Business Context and Reporting Period
This Form 8-K Current Report was filed by Labstyle Innovations Corp. on May 13, 2013, regarding events occurring on May 10, 2013. The filing details the final closing of a private placement offering of equity securities to accredited investors. Note: The input metadata references "Dariohealth Corp.", but the filing text explicitly identifies the registrant as "Labstyle Innovations Corp."
Key Financial Metrics
- Gross Proceeds: $10,000,000 raised from the sale of 40 Units.
- Net Proceeds: Approximately $8,985,510 after deducting fees and offering expenses.
- Offering Fees: $950,000 paid in cash and non-accountable allowances to the placement agent (Aegis Capital Corp.).
- Securities Issued: 4,000,000 shares of Common Stock and warrants to purchase 2,000,000 shares of Common Stock.
- Unit Pricing: $250,000 per Unit ($2.50 per share of Common Stock plus 0.5 Warrant).
- Warrant Terms: Exercise price of $5.00 per share; expiration date of April 4, 2016.
Material Changes and Transaction Details
The Company completed the final closing of an offering that began with an initial closing on April 5, 2013. A total of 126 accredited investors participated in the Offering. In addition to the investor securities, the Company issued Placement Agent Warrants to Aegis Capital Corp. to purchase an aggregate of 400,000 shares of Common Stock (200,000 at $2.50 and 200,000 at $5.00).
Guidance, Risks, and Contingencies
- Registration Obligation: The Company must file a registration statement with the SEC by July 9, 2013, to cover the resale of securities by investors. It must use commercially reasonable efforts to have this statement declared effective within 90 days of filing.
- Penalty Clause: If the registration statement is not filed or declared effective by the required dates, the Company must pay investors 0.5% of their investment every 30 days until cured, up to a maximum of 6% of the investment amount.
- Restrictions: Securities were issued under Section 4(2) of the Securities Act and Regulation D exemptions. They are restricted securities under Rule 144 and cannot be resold without registration or an applicable exemption.
Investor Verification Checklist
- Verify the identity of the registrant (Labstyle Innovations Corp.) versus the metadata label (Dariohealth Corp.).
- Confirm the status of the registration statement filing deadline (July 9, 2013) and potential penalty accruals.
- Review the dilution impact of the 4,000,000 new shares and 2,000,000 warrant shares issued.
- Assess the liquidity of the restricted securities and the timeline for potential resale registration.
- Examine the use of net proceeds ($8,985,510) in subsequent financial reports to ensure alignment with stated capital needs.